
Annual report 2021
added 12-23-2023
BiondVax Pharmaceuticals Ltd. Net Debt 2011-2026 | BVXV
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt BiondVax Pharmaceuticals Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 52 M | 18.5 M | - | -15.7 M | -33.5 M | -9.61 M | -17.9 M | -11 M | - |
All numbers in ILS currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 52 M | -33.5 M | -2.46 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 21.65 | 1.12 % | $ 1.01 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.9 | -0.18 % | $ 6.62 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
-83 M | $ 22.3 | 1.55 % | $ 3.7 B | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Cara Therapeutics
CARA
|
-20.5 M | - | -3.03 % | $ 260 M | ||
|
CASI Pharmaceuticals
CASI
|
-36.5 M | - | - | $ 35.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
ChromaDex Corporation
CDXC
|
-62 M | - | -0.88 % | $ 598 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-3.05 M | - | 17.91 % | $ 11.1 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 102.06 | -3.22 % | $ 27.2 B | ||
|
Checkpoint Therapeutics
CKPT
|
-40.8 M | - | - | $ 169 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.1 | 0.49 % | $ 438 M | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 23.42 | 0.69 % | $ 2.98 B | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.42 | -1.39 % | $ 378 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 2.92 | -0.34 % | $ 4.81 M | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
ContraFect Corporation
CFRX
|
-6.03 M | - | -5.16 % | $ 5.39 M | ||
|
Cardiff Oncology
CRDF
|
-16.6 M | $ 1.72 | - | $ 115 M | ||
|
CTI BioPharma Corp.
CTIC
|
18.3 M | - | - | $ 1.2 B | ||
|
BioXcel Therapeutics
BTAI
|
56.3 M | $ 1.09 | 2.83 % | $ 13.3 M |